Short-term weight loss and body composition changes in patients with obesity by GLP-1 and GIP/GLP-1 receptor agonists in combination with low-calorie diet.

Short-term weight loss and body composition changes in patients with obesity by GLP-1 and GIP/GLP-1 receptor agonists in combination with low-calorie diet. - Short-term therapeutic effects of GLP-1 and GIP/GLP-1 receptor agonists on patients with obesity during severe energy restriction.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053234

Enrollment

Registered

2023-12-31

Start date

2023-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with BMI of 25 kg/m2 or higher aged 18 years or older in Japan. (2) Patients who admitted to our hospital for weight loss between January 2019 and December 2023 and completed a 13 days low-calorie-diet therapy (LCD) provided by our hospital to replace their three daily meals. (3) Patients who had started using oral or subcutaneous semaglutide or tirzepatide within 8 weeks prior to and 1 week after admission, or those with no history of GLP-1 receptor agonist use

Exclusion criteria

Exclusion criteria: (1) Patients who were or plan to be pregnant. (2) Patients who were unable to cooperate with treatment due to mental illness or language barrier. (3) Patients with a history of GLP-1 receptor agonist use other than oral and subcutaneous semaglutide and tirzepatide. (4) Patients who failed to continue GLP-1 or GIP/GLP-1 receptor agonists during hospitalization. (5) Patients who were unable to continue the LCD provided by our hospital. (6) Other patients deemed inappropriate as research subjects by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Percentage changes in body composition during inpatient treatment with low-calorie diet for thirteen days.	—

Secondary

Measure	Time frame
Percentage changes in body weight and body mass index, as well as systolic and diastolic blood pressure, fasting blood glucose, C-peptide, TG, HDL-C and LDL-C and subcutaneous and visceral fat area during inpatient treatment with low-calorie diet for thirteen days.	—

Countries

Japan

Contacts

Public ContactRyoichi Ishibashi

Kimitsu Chuo Hospital epartment of Medicine, Division of Diabetes, Endocrinology and Metabolism

ishibashi-cib@umin.net0438-36-1071

Outcome results